Cécile Artaud has a Master’s degree in biomedical research from the University of Arkansas (USA, AR) completed with a university degree from the University of Sorbonne in Innovation and Entrepreneurship in Biomedical Engineering. She is now a clinical project manager with 15 years’ experience in academic vaccine development from basic research to clinical trials. She has been in charge of project conception, clinical operations, coordinating activities for GMP manufacturing, regulatory safety studies, and for preparing and conducting Phase I/II clinical trials inside and outside Europe. Clinical manager for the three Phase 1/2 clinical trials sponsored by Institut Pasteur in the last 5 years (cancer, infectious disease and gene therapy for a rare disease) she has developed a broad experience in diverse fields of expertise. She is also an expert clinical project manager in international translational research projects and has managed several sero-epidemiological projects and cohort studies in low and middle income countries (LMICs).
Click to view graph
Connections
Click to view timeline
Timeline
Transversal Projects
Projects
Former Teams
Publications
Download-
2022Safety and immunogenicity of a measles-vectored SARS-CoV-2 vaccine candidate, V591 / TMV-083, in healthy adults: results of a randomized, placebo-controlled Phase I study., EBioMedicine 2022 Jan; 75(): 103810.
-
2021Cell-Mediated Immunity to NAGLU Transgene Following Intracerebral Gene Therapy in Children With Mucopolysaccharidosis Type IIIB Syndrome., Front Immunol 2021 ; 12(): 655478.
-
2018A multicenter, randomized controlled comparison of three renutrition strategies for the management of moderate acute malnutrition among children aged from 6 to 24 months (the MALINEA project), Trials 2018 Dec;19(1):666.
-
2017Intracerebral gene therapy in children with mucopolysaccharidosis type IIIB syndrome: an uncontrolled phase 1/2 clinical trial, Lancet Neurol 2017 09;16(9):712-720.
-
2017Large-scale synthesis and structural analysis of a synthetic glycopeptide dendrimer as an anti-cancer vaccine candidate, Organic & Biomolecular Chemistry, 2017, 15, 114 - 123.
-
2016Large-scale synthesis and structural analysis of a synthetic glycopeptide dendrimer as an anti-cancer vaccine candidate, Org. Biomol. Chem. 2016 Dec;15(1):114-123.
-
2016The fully synthetic MAG-Tn3 therapeutic vaccine containing the tetanus toxoid-derived TT830-844 universal epitope provides anti-tumor immunity., Cancer Immunol Immunother 2016 Mar; 65(3): 315-25.